Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitochondrial translational initiation factor 3 (MTIF3) is a nuclear-encoded protein that is imported into mitochondria, where it plays a key role in the initiation phase of protein synthesis by binding to the small (28S) subunit of the mitochondrial ribosome. This action promotes the dissociation of mitochondrial 55S ribosomes into their 39S (large) and 28S (small) subunits, increasing the pool of available small subunits for translation initiation. MTIF3 is distinct from its bacterial counterpart in both structure and function, containing mitochondria-specific extensions and displaying different mechanisms in the assembly of the translation initiation complex. Loss of MTIF3 does not completely abolish mitochondrial translation but leads to defects such as selective reduction in the synthesis of certain proteins (e.g., ATP6), impairing the assembly of mitochondrial ATP synthase and mitochondrial energy production. Genetic variants in MTIF3 have been associated with combined oxidative phosphorylation deficiency and may play a role in neurodegenerative diseases, including Parkinson’s disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitochondrial translational initiation factor 3 (MTIF3).